IKT
Inhibikase TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
First-patient enrollment in IMPROVE-PAH confirms the program has moved from planning into execution, and the 10-K shows $178.8 million of cash, cash equivalents, and marketable securities with management stating this funds normal operations for at least twelve months from the March 26, 2026 filing date [#8-K-2026-04-07] [#10-K-2026-03-26]. At roughly a $243 million market cap, that leaves a relatively modest enterprise value for a single-asset Phase 3 PAH story if enrollment and safety hold up.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Additional capital may be required before full value realization despite current cash runway
Momentum
84
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.50 · Bull $3.40 · Bear $0.70
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $5.75
Why
Momentum84 · Δ7d -
Value41 · Δ7d +0.1
Sentiment51 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
84
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
51
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 84.3 / Value 41.1 / Sentiment 50.9
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$224.46M
Beta
0.84
Shares Out
120.9M
P/E (TTM) · Derived
-1.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.09
Rev YoY
-100.0%
EPS YoY
+79.6%
Gross Margin
-
Op Margin
-23885.1%
Net Debt
-$97.54M
Current Ratio
11.73
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology